In serous cystadenocarcinoma samples, the positive expression rates of MAGE-1 and MAGE-3 were 77.8% (14/18) and 66.7% (12/18), which were significantly higher than that in other types of ovarian cancer (P < 0.05). This evidence concerns the gene MAGEA3 and ovarian carcinoma.